{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T03:41:09Z","timestamp":1770781269126,"version":"3.50.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2012,12,21]],"date-time":"2012-12-21T00:00:00Z","timestamp":1356048000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s12094-012-0979-8","type":"journal-article","created":{"date-parts":[[2012,12,20]],"date-time":"2012-12-20T12:21:03Z","timestamp":1356006063000},"page":"619-625","source":"Crossref","is-referenced-by-count":13,"title":["Polymorphism of TS 3\u2032-UTR predicts survival of Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel"],"prefix":"10.1007","volume":"15","author":[{"given":"J.","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Q.","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Hua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,21]]},"reference":[{"key":"979_CR1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/1471-2407-11-151","volume":"11","author":"D Yan","year":"2011","unstructured":"Yan D, Dai H, Liu JW (2011) Serum levels of MMP-11 correlate with clinical outcome in Chinese patients with advanced gastric adenocarcinoma. BMC Cancer 11:151\u2013158","journal-title":"BMC Cancer"},{"key":"979_CR2","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2008.19.1718","volume":"27","author":"E Goekkurt","year":"2009","unstructured":"Goekkurt E, Al-Batran SE, Hartmann JT et al (2009) Pharmacogenetic\u2014analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. J Clin Oncol 27:2863\u20132873","journal-title":"J Clin Oncol"},{"key":"979_CR3","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1186\/1471-2407-10-583","volume":"10","author":"H Lim do","year":"2010","unstructured":"Lim do H, Park SH, Park KW et al (2010) Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer. BMC Cancer 10:583\u2013589","journal-title":"BMC Cancer"},{"key":"979_CR4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","volume":"358","author":"D Cunningham","year":"2008","unstructured":"Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36\u201346","journal-title":"N Engl J Med"},{"key":"979_CR5","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/annonc\/mdn717","volume":"20","author":"YK Kang","year":"2009","unstructured":"Kang YK, Kang WK, Shin DB et al (2009) Capecitabine\/cisplatin versus 5-fluorouracil\/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 20:666\u2013673","journal-title":"Ann Oncol"},{"key":"979_CR6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00280-008-0903-7","volume":"64","author":"N Baize","year":"2009","unstructured":"Baize N, Abakar-Mahamat A, Mounier N et al (2009) Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric\u00a0carcinoma after failure of cisplatin-based regimens. Cancer Chemother Pharmacol 64:549\u2013555","journal-title":"Cancer Chemother Pharmacol"},{"key":"979_CR7","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/sj.bjc.6604186","volume":"98","author":"HJ Kang","year":"2008","unstructured":"Kang HJ, Chang HM, Kim TW et al (2008) A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer. Br J Cancer 98:316\u2013322","journal-title":"Br J Cancer"},{"key":"979_CR8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/1471-2407-11-177","volume":"11","author":"J Gao","year":"2011","unstructured":"Gao J, Lu M, Yu JW et al (2011) Thymidine Phosphorylase\/b-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel. BMC Cancer 11:177\u2013184","journal-title":"BMC Cancer"},{"key":"979_CR9","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3748\/wjg.14.617","volume":"14","author":"KH Yu","year":"2008","unstructured":"Yu KH, Wang WX, Ding YM et al (2008) Polymorphism of thymidylate synthase gene associated with its protein expression in human colon cancer. World J Gastroenterol 14:617\u2013621","journal-title":"World J Gastroenterol"},{"key":"979_CR10","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1200\/JCO.2005.04.8322","volume":"24","author":"A Ruzzo","year":"2006","unstructured":"Ruzzo A, Graziano F, Kawakami K et al (2006) Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol 24:1883\u20131891","journal-title":"J Clin Oncol"},{"key":"979_CR11","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00280-008-0815-6","volume":"63","author":"ZH Huang","year":"2009","unstructured":"Huang ZH, Hua D, Li LH (2009) The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population. Cancer Chemother Pharmacol 63:911\u2013918","journal-title":"Cancer Chemother Pharmacol"},{"key":"979_CR12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/sj.tpj.6500012","volume":"1","author":"ST Pullarkat","year":"2001","unstructured":"Pullarkat ST, Stoehlmacher J, Ghaderi V et al (2001) Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 1:65\u201370","journal-title":"Pharmacogenomics J"},{"key":"979_CR13","first-page":"3700","volume":"9","author":"T Tsuji","year":"2003","unstructured":"Tsuji T, Hidaka S, Sawai T et al (2003) Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. Clin Cancer Res 9:3700\u20133704","journal-title":"Clin Cancer Res"},{"key":"979_CR14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"979_CR15","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1158\/1055-9965.EPI-09-1257","volume":"19","author":"K Shitara","year":"2010","unstructured":"Shitara K, Muro K, Ito S et al (2010) Folate intake along with genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase in patients with advanced gastric cancer. Cancer Epidemiol Biomarkers Prev 19:1311\u20131319","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"979_CR16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1751-2980.2009.00373.x","volume":"10","author":"YH Cui","year":"2009","unstructured":"Cui YH, Liu TS, Zhuang RY et al (2009) Polymorphism of thymidylate synthase gene and chemosensitivity of 5-fluorouracil regimen in metastatic gastrointestinal cancer. J Dig Dis 10:118\u2013123","journal-title":"J Dig Dis"},{"key":"979_CR17","first-page":"127","volume":"22","author":"BG Seo","year":"2009","unstructured":"Seo BG, Kwon HC, Oh SY et al (2009) Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI. Oncol Rep 22:127\u2013136","journal-title":"Oncol Rep"},{"key":"979_CR18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.arcmed.2010.01.001","volume":"41","author":"X Dong","year":"2010","unstructured":"Dong X, Wu J, Liang P et al (2010) Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and gastric cancer: a meta-analysis. Arch Med Res 41:125\u2013133","journal-title":"Arch Med Res"},{"key":"979_CR19","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/13547500701546766","volume":"12","author":"S Boccia","year":"2007","unstructured":"Boccia S, Gianfagna F, Persiani R et al (2007) Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and susceptibility to gastric adenocarcinoma in an Italian population. Biomarkers 12:635\u2013644","journal-title":"Biomarkers"},{"key":"979_CR20","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ejca.2005.10.020","volume":"42","author":"M Lacasa\u00f1a-Navarro","year":"2006","unstructured":"Lacasa\u00f1a-Navarro M, Galv\u00e1n-Portillo M, Chen J et al (2006) Methylenetetrahydrofolate reductase 677C>T polymorphism and gastric cancer susceptibility in Mexico. Eur J Cancer 42:528\u2013533","journal-title":"Eur J Cancer"},{"key":"979_CR21","doi-asserted-by":"crossref","first-page":"569","DOI":"10.7314\/APJCP.2012.13.2.569","volume":"13","author":"S Gao","year":"2012","unstructured":"Gao S, Liu N, Ma Y et al (2012) Methylenetetrahydrofolate reductase gene polymorphisms as predictive and prognostic biomarkers in ovarian cancer risk. Asian Pac J Cancer Prev 13:569\u2013573","journal-title":"Asian Pac J Cancer Prev"},{"key":"979_CR22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00384-009-0779-y","volume":"25","author":"AM Fern\u00e1ndez-Peralta","year":"2010","unstructured":"Fern\u00e1ndez-Peralta AM, Daimiel L, Nejda N et al (2010) Association of polymorphisms MTHFR C677T and A1298C with risk of colorectal cancer, genetic and epigenetic characteristic of tumors, and response to chemotherapy. Int J Colorectal Dis 25:141\u2013151","journal-title":"Int J Colorectal Dis"},{"key":"979_CR23","first-page":"455","volume":"18","author":"G Osian","year":"2009","unstructured":"Osian G, Procopciuc L, Vlad L et al (2009) C677T and A1298C mutations in the MTHFR gene and survival in colorectal cancer. J Gastrointestin Liver Dis 18:455\u2013460","journal-title":"J Gastrointestin Liver Dis"},{"key":"979_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/PL00008711","volume":"104","author":"AB Kuilenburg Van","year":"1999","unstructured":"Van Kuilenburg AB, Vreken P, Abeling NG et al (1999) Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet 104:1\u20139","journal-title":"Hum Genet"},{"key":"979_CR25","doi-asserted-by":"crossref","first-page":"x263","DOI":"10.1093\/annonc\/mdl271","volume":"10","author":"J Stoehlmacher","year":"2006","unstructured":"Stoehlmacher J (2006) The impact of genomics and proteomics in the clinic: functional genetic polymorphisms and their value in response and toxicity prediction in solid tumours. Ann Oncol 10:x263\u2013x268","journal-title":"Ann Oncol"},{"key":"979_CR26","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1158\/1535-7163.MCT-06-0327","volume":"5","author":"A Morel","year":"2006","unstructured":"Morel A, Boisdron-Celle M, Fey L et al (2006) Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther 5:2895\u20132904","journal-title":"Mol Cancer Ther"},{"key":"979_CR27","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/01.GIM.0000118061.66602.A5","volume":"6","author":"N Salgueiro","year":"2004","unstructured":"Salgueiro N, Veiga I, Fragoso M et al (2004) Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-Fluorouracil toxicity in Portuguese colorectal cancer patients. Genet Med 6:102\u2013107","journal-title":"Genet Med"},{"key":"979_CR28","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/bjc.1997.29","volume":"75","author":"SA Ridge","year":"1997","unstructured":"Ridge SA, Brown O, McMurrough J et al (1997) Mutations at codon 974 of the DPYD gene are a rare event. Br J Cancer 75:178\u2013179","journal-title":"Br J Cancer"},{"key":"979_CR29","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1373\/49.10.1661","volume":"49","author":"R Ahluwalia","year":"2003","unstructured":"Ahluwalia R, Freimuth R, McLeod HL et al (2003) Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase. Clin Chem 49:1661\u20131664","journal-title":"Clin Chem"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-012-0979-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-012-0979-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-012-0979-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T03:51:34Z","timestamp":1559447494000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-012-0979-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,21]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["979"],"URL":"https:\/\/doi.org\/10.1007\/s12094-012-0979-8","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,21]]}}}